Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ELI LILLY AND COMPANY

(LLY)
  Report
Delayed Nyse  -  04:03:13 2023-01-26 pm EST
348.01 USD   -0.49%
02:18pU.S. FDA pulls authorization for AstraZeneca's COVID-19 treatment Evusheld
RE
10:17aEli Lilly Earmarks $1 Million to Boost Cold Chain Capacity in 17 Countries
MT
10:01aLilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sector Update: Health Care Stocks Rising in Defensive Thursday Trading

09/22/2022 | 01:48pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -0.49% 348.01 Delayed Quote.-5.32%
INTUITIVE SURGICAL, INC. 2.77% 250.55 Delayed Quote.-8.12%
LUNA INNOVATIONS INCORPORATED -1.63% 9.06 Delayed Quote.4.78%
MEDIWOUND LTD. 1.31% 13.88 Delayed Quote.0.22%
NASDAQ COMPOSITE 1.76% 11512.41 Real-time Quote.8.09%
All news about ELI LILLY AND COMPANY
02:18pU.S. FDA pulls authorization for AstraZeneca's COVID-19 treatment Evusheld
RE
10:17aEli Lilly Earmarks $1 Million to Boost Cold Chain Capacity in 17 Countries
MT
10:01aLilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold ..
PR
01/24Eli Lilly to invest $450 million more to expand diabetes drug plant capacity
RE
01/24Eli Lilly to Allocate Another $450 Million Toward Manufacturing Capacity Expansion at N..
MT
01/24Eli Lilly Plans $450 Million Investment To Expand US Manufacturing Site
MT
01/24Eli Lilly to invest $450 mln to expand diabetes drug plant capacity
RE
01/24Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangl..
PR
01/24Eli Lilly and Company Plans to Invest Additional $450 Million At Manufacturing Site in ..
CI
01/23Global markets live: Abbott, Goldman Sachs, Alphabet, Eli Lilly, Pay..
MS
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2022 28 656 M - -
Net income 2022 6 097 M - -
Net Debt 2022 11 017 M - -
P/E ratio 2022 53,1x
Yield 2022 1,06%
Capitalization 332 B 332 B -
EV / Sales 2022 12,0x
EV / Sales 2023 11,2x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 349,73 $
Average target price 378,23 $
Spread / Average Target 8,15%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Alonzo Weems Senior VP, Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY-5.32%332 306
JOHNSON & JOHNSON-4.72%443 181
NOVO NORDISK A/S1.07%313 303
ROCHE HOLDING AG1.07%281 267
MERCK & CO., INC.-2.13%275 319
ABBVIE INC.-8.55%261 275